Compounded "semaglutide" is not FDA approved semaglutide.com The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law